Nanovibronix Stock Today

NAOV -  USA Stock  

USD 2.18  0.08  3.81%

Nanovibronix is selling for under 2.18 as of the 17th of September 2021; that is 3.81 percent increase since the beginning of the trading day. The stock's lowest day price was 2.01. Nanovibronix has about a 43 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Nanovibronix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of June 2020 and ending today, the 17th of September 2021. Click here to learn more.
 Market Performance
8 of 100
  Odds Of Distress
Less than 43

Nanovibronix Stock Profile

The next fiscal quarter end is expected on the 30th of September 2021. NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York. Nanovibronix operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. more on Nanovibronix
Nanovibronix is way too risky over 90 days horizon
Nanovibronix appears to be risky and price may revert if volatility continues
Nanovibronix was previously known as NanoVibronix and was traded on NASDAQ Exchange under the symbol NVBXU.
The company reported the previous year's revenue of 661 K. Net Loss for the year was (7.06 M) with profit before overhead, payroll, taxes, and interest of 214 K.
Nanovibronix currently holds about 5.67 M in cash with (4.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Nanovibronix has a frail financial position based on the latest SEC disclosures
Roughly 12.0% of the company outstanding shares are owned by corporate insiders
Latest headline from www.equities.com: NanoVibronix falls 3.38 percent for September 10 - Equities.com
Nanovibronix Fama & French Medical Equipment
Medical Equipment
Fama & French Classification
Nanovibronix SEC Filings
Nanovibronix SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameNanovibronix
Older SymbolNVBXU
CEO, DirectorBrian Murphy  (View All)
Average Analyst Recommendation
Analysts covering Nanovibronix report their recommendations after researching Nanovibronix's financial statements, talking to executives and customers, or listening in on Nanovibronix's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Nanovibronix. The Nanovibronix consensus assessment is calculated by taking the average forecast from all of the analysts covering Nanovibronix.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Nanovibronix based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Nanovibronix financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares11.1 M10.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted11.1 M10.3 M
Significantly Up
Increasing
Slightly volatile
Total Assets8.9 M8.2 M
Significantly Up
Increasing
Slightly volatile
Total Liabilities6.3 M5.8 M
Significantly Up
Increasing
Stable
Current Assets8.6 MM
Significantly Up
Increasing
Slightly volatile
Current Liabilities3.1 M2.9 M
Significantly Up
Increasing
Stable
Total Debt28.6 K27.9 K
Fairly Up
Decreasing
Slightly volatile
Gross Margin0.420.343
Fairly Up
Decreasing
Slightly volatile
Asset Turnover0.170.172
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Nanovibronix's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Nanovibronix's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Nanovibronix's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nanovibronix's financial leverage. It provides some insight into what part of Nanovibronix's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Nanovibronix's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Nanovibronix deploys its capital and how much of that capital is borrowed.
Liquidity
Nanovibronix cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 22 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Nanovibronix has a current ratio of 16.5, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(3.48 Million)Share
Nanovibronix (NAOV) is traded on NASDAQ Exchange in USA. It is located in 525 Executive Boulevard and employs 11 people. Nanovibronix was previously known as NanoVibronix and was traded on NASDAQ Exchange under the symbol NVBXU. Nanovibronix is listed under Medical Equipment category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 55.21 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nanovibronix's market, we take the total number of its shares issued and multiply it by Nanovibronix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Nanovibronix conducts business under Healthcare sector and is part of Medical Devices industry. The entity has 24.11 M outstanding shares of which 4.18 M shares are now shorted by private and institutional investors with about 0.1 trading days to cover. Nanovibronix currently holds about 5.67 M in cash with (4.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Check Nanovibronix Probability Of Bankruptcy
Ownership
Nanovibronix maintains a total of twenty-four million one hundred ten thousand outstanding shares. Nanovibronix secures 12.15 % if its outstanding shares held by insiders and 12.15 % owned by institutional investors . Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Nanovibronix Ownership Details

Nanovibronix Stock Price Odds Analysis

What are Nanovibronix's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Nanovibronix jumping above the current price in 90 days from now is about 33.71%. The Nanovibronix probability density function shows the probability of Nanovibronix stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 7.2534. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nanovibronix will likely underperform. In addition to that, the company has an alpha of 3.528, implying that it can generate a 3.53 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 2.18HorizonTargetOdds Up 2.18 
66.23%90 days
 2.18 
33.71%
Based on a normal probability distribution, the odds of Nanovibronix to move above the current price in 90 days from now is about 33.71 (This Nanovibronix probability density function shows the probability of Nanovibronix Stock to fall within a particular range of prices over 90 days) .

Nanovibronix Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Nanovibronix that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nanovibronix's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nanovibronix's value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares308.9 K263 K
Amtrust Financial Services IncCommon Shares146.1 K124 K
View Nanovibronix Diagnostics

Nanovibronix Historical Income Statement

Nanovibronix Income Statement is one of the three primary financial statements used for reporting Nanovibronix's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Nanovibronix revenue and expense. Nanovibronix Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Nanovibronix Cost of Revenue is fairly stable at the moment as compared to the past year. Nanovibronix reported Cost of Revenue of 409,000 in 2020. Interest Expense is likely to climb to about 147.2 K in 2021, whereas Earning Before Interest and Taxes EBIT is likely to drop (4.5 M) in 2021. View More Fundamentals

Nanovibronix Stock Against Markets

Picking the right benchmark for Nanovibronix stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nanovibronix stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nanovibronix is critical whether you are bullish or bearish towards Nanovibronix at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nanovibronix without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Nanovibronix Corporate Directors

Nanovibronix corporate directors refer to members of a Nanovibronix board of directors. The board of directors generally takes responsibility for the Nanovibronix's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Nanovibronix's board members must vote for the resolution. The Nanovibronix board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Thomas Mika - Independent DirectorProfile
Harold Jacob - Chief Medical Officer, DirectorProfile
Martin Goldstein - DirectorProfile
Michael Ferguson - Independent DirectorProfile
Additionally, see Stocks Correlation. Note that the Nanovibronix information on this page should be used as a complementary analysis to other Nanovibronix's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Nanovibronix Stock analysis

When running Nanovibronix price analysis, check to measure Nanovibronix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanovibronix is operating at the current time. Most of Nanovibronix's value examination focuses on studying past and present price action to predict the probability of Nanovibronix's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nanovibronix's price. Additionally, you may evaluate how the addition of Nanovibronix to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
The market value of Nanovibronix is measured differently than its book value, which is the value of Nanovibronix that is recorded on the company's balance sheet. Investors also form their own opinion of Nanovibronix's value that differs from its market value or its book value, called intrinsic value, which is Nanovibronix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nanovibronix's market value can be influenced by many factors that don't directly affect Nanovibronix underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nanovibronix's value and its price as these two are different measures arrived at by different means. Investors typically determine Nanovibronix value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nanovibronix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.